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Abstract
The expression of recombinant hemagglutinin in plants is a promising alternative to
the current egg-based production system for the influenza vaccines. Protein-
stabilizing fusion partners have been developed to overcome the low production
yields and the high downstream process costs associated with the plant expression
system. In this context, we tested the fusion of hydrophobin I to the hemagglutinin
ectodomain of the influenza A (H1N1)pdm09 virus controlled by the hybrid
En2PMA4 transcriptional promoter to rapidly produce high levels of recombinant
antigen by transient expression in agro-infiltrated Nicotiana benthamiana leaves.
The fusion increased the expression level by a factor of ,2.5 compared to the
unfused protein allowing a high accumulation level of 8.6% of the total soluble
proteins. Hemagglutinin was located in ER-derived protein bodies and was
successfully purified by combining an aqueous-two phase partition system and a
salting out step. Hydrophobin interactions allowed the formation of high molecular
weight hemagglutinin structures, while unfused proteins were produced as
monomers. Purified protein was shown to be biologically active and to induce
neutralizing antibodies after mice immunization. Hydrophobin fusion to influenza
hemagglutinin might therefore be a promising approach for rapid, easy, and low
cost production of seasonal or pandemic influenza vaccines in plants.
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Introduction
Influenza infections are of major concern for public health. Pandemics have
caused more than 50 million deaths and cumulatively more have been caused by
seasonal infections [1]. Vaccination has been widely used since the early 1960’s to
prevent contamination. Millions of doses are being produced yearly based on the
well established egg-based system developed in 1941 [2]. Nevertheless, emerging
problems have pointed out the need for new platforms for influenza vaccine
production [3]. These alternative systems should be flexible regarding strain
changes and rapid with respect to pandemics. Plants were recently proposed as a
platform for vaccine production with the benefits of low cultivation costs, rapid
biomass availability, ease of scaling-up, and limited risks of pathogen
contamination [4]. Moreover, transient expression in leaves allows for the rapid
and high-level production of pharmacological proteins [5].
Hemagglutinin (HA), the most immunogenic protein of the influenza virus, is
the main target for recombinant influenza vaccine development. In plants,
Influenza antigens were first expressed transiently in Nicotiana benthamiana leaves
as a chimeric protein composed of an HA fragment fused to a fragment of
neuraminidase, both from an H5N1 influenza strain, as well as to a thermostable
lichenase [6]. Two approaches based on the expression of the HA protein alone
were investigated. Firstly, full-length HAs from H1N1 (A/New Caledonia/20/99)
and H5N1 (A/Indonesia/05/05) viruses were expressed transiently in N.
benthamiana as virus-like particles (VLP) that bud from the plasma membrane
[7]. A successful phase II clinical trial was achieved by Medicago with HA-VLPs
from an avian H5 influenza strain [8]. Secondly, expression of a soluble truncated
HA construct from A/Wyoming/03/03 (H3N2) was achieved by removal of the
transmembrane domain and the addition of a KDEL retention signal [9]. This
approach was used to express the HA from three 2008–2009 seasonal strains as
well as the 2009 swine pandemic H1N1 (A/California/04/09) strain, an avian
H5N1 (A/Indonesia/05/05) strain [10–11], and a low pathogenic avian H7N7
strain [12]. Recently, the soluble truncated HA from the pandemic A/California/
04/09 (H1N1) was shown to be safe and immunogenic in a phase I clinical trial
[13]. Both the VLP and the truncated HA approaches were shown to be a feasible
response strategy to pandemics in developing countries, by the stable and
transient expression of full-length or truncated HA from an avian H5 influenza
strain in Nicotiana tabacum plants [14].
To enhance the accumulation level and to simplify the downstream purification
procedure, the recombinant protein can be fused to a protein-stabilizing partner
such as zein from plants, elastin from animals, and hydrophobin from fungi
(reviewed in [15]). Hydrophobin I (HFBI), a small (,10 kDa) surface-active
protein secreted by filamentous fungi, possesses the ability to alter the
hydrophobicity of the fusion partner, which can therefore be purified by an
aqueous two-phase system (ATPS) [16]. This approach has been successfully used
in N. benthamiana agro-infiltrated leaves and N. tabacum BY-2 cells for the
expression of GFP in ER-derived protein bodies (PB) [17–18]. However, fusion of
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HFBI to the HA ectodomain from the Influenza A/Hatay/2004 (H5N1) virus in
transgenic N. tabacum plants did not improve its expression compared with non-
fused HA [19], while the fusion of elastin-like polypeptide (ELP) to the same HA
ectodomain increased its accumulation level by 10-fold without compromising its
functionality [19–20].
In the present study, we investigated hydrophobin fusion as a tool to obtain
high-level expression of the recombinant HA ectodomain from the Influenza A/
Texas/05/2009 (H1N1) virus by transient expression in N. benthamiana leaves.
High expression levels of H1-HFBI in ER-derived protein bodies were obtained.
H1-HFBI was easily and efficiently purified by ATPS. The immunogenic
properties and the potency to induce neutralizing antibodies of the purified
antigen were demonstrated by immunological studies in mice.
Results
Transient expression of H1-HFBI
The sequence encoding the HA ectodomain (codons 18–529) of the A/Texas/05/
2009 (H1N1) influenza virus was fused to the Arabidopsis thaliana endochitinase
signal peptide sequence at the 59 end, and to the endoplasmic reticulum (ER)
retention KDEL sequence at the 39 end giving H1 (Fig. 1). In addition, the
sequence encoding HFBI was fused downstream of the HA ectodomain, via a
GGGSGGGS linker, to generate H1-HFBI (Fig. 1) and promote PB formation in
the ER. The two resulting sequences were plant codon-optimized (S1 Fig.), and
cloned into the binary vector pEAQ-specialK-HT [21], except that the CaMV 35S
promoter had been replaced by the En2PMA4 promoter, a hybrid promoter made
of the Nicotiana plumbaginifolia PMA4 promoter [22] reinforced by two copies of
the CaMV 35S enhancer [23]. We indeed found that the latter allowed higher GFP
expression than the former when transiently expressed in N. benthamiana leaves
(S2 Fig.). The resulting binary vector was electroporated into Agrobacterium
tumefaciens LBA4404virG, a strain that constitutively expresses virG and allows T-
DNA transfer in the absence of the phenolic inducer, acetosyringone [24]. In a
preliminary test, the effect of acetosyringone in the infiltration medium on the
transient expression of H1-HFBI in N. benthamiana leaves was quantified by
Western blotting analysis of 16 independent samples collected 6 dpi (S3 Fig.). A
30% decrease of H1-HFBI from 9.7% of total soluble proteins (TSP) to 6.9% TSP
was observed in the presence of acetosyringone. Taking into account the HFBI
contribution to the H1-HFBI size (11.7%), the actual expression level of H1 was
8.6% TSP and 6.1%, in the presence or absence of AS, respectively.
N. benthamiana leaves were therefore agro-infiltrated with the H1 and H1-
HFBI constructs in the absence of acetosyringone, and the expression level of both
proteins was analyzed by SDS-PAGE of the soluble protein extracts (Fig. 2a). High
expression levels were observed by Coomassie blue staining for both proteins in
four individual infiltration experiments. To confirm this observation, Western
blotting analysis was performed with polyclonal anti-influenza A antibodies
Influenza Hemagglutinin Vaccine
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(Fig. 2b). For H1-HFBI, two bands were detected, the major band at an apparent
size of 80 kDa and a less abundant band at a size corresponding to untagged H1.
This suggests that the H1-HFBI protein was partially cleaved, possibly close to the
linker. Regarding their relative abundance, dilution series of three samples
containing H1-HFBI were quantified and the resulting signals were compared
with the signal of the undiluted samples containing untagged H1 derived from the
Fig. 1. Schematic representation of the pEAQ plasmids used to express H1-HFBI and H1. RB and LB: right and left T-DNA borders, En2PMA4: N.
plumbaginifolia (NpPMA4) promoter reinforced by two copies of the CaMV 35S enhancer (De Muynck et al., 2009); 59 and 39UTR: Cowpea Mosaic Virus
Untranslated Regions (translational enhancers); SP: A. thaliana basic endochitinase signal peptide, HA: hemagglutinin ectodomain (residues 18 to 529),
HFBI: hydrophobin I; KDEL: ER retention signal; pNos, NosT: nopaline synthase gene promoter or terminator; p35S, 35ST: Cauliflower Mosaic Virus 35S
promoter or terminator; p19: suppressor of RNA silencing; nptII: neomycin phosphotransferase II gene.
doi:10.1371/journal.pone.0115944.g001
Fig. 2. Accumulation of HA fused or not to HFBI. The H1 and H1-HFBI constructs were transiently
expressed in N. benthamiana leaves. One construct was abaxially infiltrated on one half of the leaf and the
other one on the other half. (a) Coomassie-blue stained gel of 30 mg TSP from four representative extracts.
TSP from a plant infiltrated with an A. tumefaciens strain containing an empty vector was used as a negative
control (C-). The bands corresponding to H1-HFBI and H1 are indicated by an arrow. (b) Western blot analysis
of 5 mg TSP coming from the same extracts as in (a). The signal was detected with polyclonal anti-influenza A.
doi:10.1371/journal.pone.0115944.g002
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same leaf (S4 Fig.). This quantification showed that the HFBI fusion enhances the
HA expression level by a factor of ,2.5.
H1-HFBI accumulates in ER-derived protein bodies
The HFBI fusion is reported to induce the formation of PBs in plants and in plant
suspension cells [15]. To determine whether this was the case for H1-HFBI, we
sought to visualize such structures in agro-infiltrated leaves by in situ
immunolocalization, however the negative control already gave too strong of a
fluorescence background. We thus transformed N. tabacum BY-2 cells with both
constructs and performed in situ immunolocalization of H1-HFBI and untagged
H1 in transgenic cells. Confocal microscopy analysis indicated a signal with a
reticulate pattern possibly corresponding to the ER (Fig. 3b). Small spherical
particles were detected with a size ranging from 0.2 to 0.5 mm (Figs. 3c and d),
reminiscent of protein body structures recently described for GFP-HFBI expressed
in N. tabacum BY-2 cells [18].
To support the ER localization of H1-HFBI, we relied on Endoglycosidase H
(EndoH) which specifically cleaves high-mannose N-glycans added in the ER, but
not complex N-glycans typically found in glycoproteins that reach the Golgi
apparatus. EndoH digestion of a leaf extract with H1-HFBI significantly decreased
its apparent size (Fig. 4), indicating that H1-HFBI was glycosylated and efficiently
retained in the ER.
Purification of H1-HFBI protein by aqueous two-phase separation
H1-HFBI was purified from agro-infiltrated leaf extracts by ATPS using Triton X-
114 as a surfactant [18, 25]. In ATPS, hydrophobin fusion partners are
concentrated within micellar structures and partitioned in a surfactant-rich phase,
while the majority of endogenous proteins remain in the aqueous phase and can
be discarded. Hydrophobin-fused proteins can be back-extracted by the addition
of a non denaturing organic solvent such as isobutanol. To assess the purity of
H1-HFBI following ATPS purification, the leaf extract and the ATPS phases were
analyzed by SDS-PAGE (Fig. 5). The majority of soluble proteins, including the
Rubisco large subunit (,55 kDa), the most abundant protein in plant leaves, were
discarded during the first separation phase. H1-HFBI was found to concentrate in
the lower phase with an estimated recovery of about 70% and an overall purity of
50% (as calculated from the signal quantification). The bands corresponding to
the five residual contaminating proteins (,35, 26, 23, 22, and 20 kDa) were
excised, trypsin digested, and analyzed by MALDI-TOFTOF mass spectrometry.
Their identity, which was confirmed by directly analyzing an ATPS-purified
sample by LC-MALDI-TOFTOF mass spectrometry analysis, is given in S1 Table.
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Fig. 3. H1-HFBI is found as protein bodies in transgenic N. tabacum BY-2 suspension cells. Wild-type
cells (a), cells expressing H1 (b) and cells expressing H1-HFBI (c–e) at the exponential phase (3 days after
dilution) were submitted to in situ immunolocalization as described in the Experimental procedures using an
FITC-conjugated anti-influenza H1N1. Bars 525 mm (a, b, c) and 5 mm (d, e).
doi:10.1371/journal.pone.0115944.g003
Fig. 4. Endoglycosidase H treatment of H1-HFBI. Time course incubation of a leaf TSP extract (5 mg) in the
presence (+) or absence (2) of endoglycosidase H (0.2 U/ml). Samples were analyzed by Western blotting
after 0, 15, or 60 min of incubation. The signal was detected with polyclonal anti-influenza A antibodies.
doi:10.1371/journal.pone.0115944.g004
Influenza Hemagglutinin Vaccine
PLOS ONE | DOI:10.1371/journal.pone.0115944 December 26, 2014 6 / 23
H1-HFBI oligomerizes and exhibits hemagglutination activity
A routine method to demonstrate the biological activity of HA is the
hemagglutination assay, which tests its ability to agglutinate red blood cells
(RBCs) in vitro by binding to sialic acids on surface proteins. We compared cell
extracts derived from leaves agro-infiltrated with the H1 or H1-HFBI constructs
in a hemagglutination assay and found that the cell extract that contained H1-
HFBI was able to agglutinate chicken RBCs, while a cell extract that contained
untagged H1 was not (Fig. 6a). A prerequisite for hemagglutination is the
formation of oligomeric HA structures that can crosslink cells, and this result
indicates that untagged H1 is probably present in a monomeric state while fusion
with HFBI allows its oligomerization.
As recombinant HA has been observed as monomers, dimers, trimers, and/or
high molecular weight oligomers (HMWO) [26], ATPS-purified H1-HFBI was
analyzed by size exclusion chromatography to determine its quaternary structure
(Fig. 7). The first peak eluted slightly after the void volume of Blue dextran and
corresponds to a size higher than the 669 kDa standard. Western blot analysis
indicated the presence of H1-HFBI in this peak at an elution volume of 15–17 ml.
Elution of the second peak took place between the 158 and 44 kDa standards.
Fig. 5. Purification of H1-HFBI by ATPS. A TSP extract from H1-HFBI-expressing leaves was subjected to
purification by ATPS as described in the Experimental procedures. Samples (40 ml) of TSP, the upper phase
discarded after the first phase separation, and the lower phase recovered after the second phase separation,
were analyzed by SDS-PAGE. The identification of bands 1–5 by mass spectrometry is reported in S1 Table.
doi:10.1371/journal.pone.0115944.g005
Influenza Hemagglutinin Vaccine
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Western blot analysis indicated the presence of H1-HFBI at an elution volume of
28–30 ml, which probably corresponds to a monomeric form (the expected size
was 68,1 kDa excluding the contribution of glycosylation). We can therefore
conclude that H1-HFBI forms both HMWO and monomers. The anti-HA signal
detected in the fractions collected for the two forms was quantified after Western
blotting and a ratio of HMWO/monomer of approximately 2 was determined.
The ATPS-purified H1-HFBI sample was also subjected to a hemagglutination
test with bovine serum albumin (BSA) as a negative control and inactivated A/
Texas/05/2009(H1N1) virus as a positive control (Fig. 6b). Hemagglutination was
Fig. 6. Hemagglutination assay. (a) Hemagglutination assay was performed as indicated in Material and
methods using serial two-fold diluted samples of duplicate (R1, R2) TSP fractions extracted from leaves
expressing H1-HFBI or untagged H1. The two bottom rows contain inactivated A/Texas/05/2009(H1N1) virus
as a positive control or a GFP-HFBI extract as a negative control. (b) Hemagglutination assay using serial
two-fold diluted samples of ATPS-purified H1-HFBI (triplicates, R1–R3). The two bottom rows contain bovine
serum albumin as a negative control or inactivated A/Texas/05/2009(H1N1) virus as a positive control. The
hemagglutination titer (HT) or the amount of hemagglutination units (HAU) was calculated according to the
well with the highest dilution giving a complete hemagglutination. This test was also used to quantify
inactivated virus concentration in terms of HAU for inhibition assay.
doi:10.1371/journal.pone.0115944.g006
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observed with H1-HFBI concentrations of 0.06 mg/well or higher, as well as with
the inactivated virus. No hemagglutination was observed with lower H1-HFBI
concentrations or with BSA. The HA titer was calculated to be 64 (26). This test
demonstrates that hydrophobin-fused HA has retained its receptor binding
activity after ATPS purification.
Immunogenicity of H1-HFBI
Prior to mice immunization, ATPS-purified H1-HFBI required further purifica-
tion to remove the remaining contaminants. Varied concentrations of ammonium
sulfate were tested for selective precipitation by salting out. Most of H1-HFBI
precipitated at 5% saturation of ammonium sulfate while the five contaminating
proteins remained in the supernatant (Fig. 8). Increasing the ammonium sulfate
concentration to 10% saturation allowed for the complete precipitation of H1-
HFBI, which appeared as a single band by SDS-PAGE (Fig. 8), indicating that the
protein was purified to apparent homogeneity in the final pellet (for this last step,
a recovery of ,90% with a purity .95% was determined by quantification of the
signals). The H1-HFBI precipitate was dissolved in PBS and dialyzed in order to
remove excess salts. H1-HFBI exhibited the same hemagglutination activity as
shown previously (S5 Fig.) and the same profile as that obtained after size
exclusion chromatography (Fig. 7).
Fig. 7. Analysis of the H1-HFBI quaternary structure by size exclusion chromatography. (a) ATPS-
purified H1-HFBI (200 mg) was injected onto a Superdex G200 size exclusion column as described in the
Experimental procedures. Elution was fractionated in 1 ml aliquots. The logarithmic size of the standards
(black square) is plotted according to their elution volume and peaks corresponding to H1-HFBI are indicated
(red dot). (b) Fractions eluted at 14 ml to 18 ml and 27 ml to 31 ml were analyzed by Western blotting with an
anti-influenza H1N1 and an anti-goat HRP-conjugated secondary antibody, and the signal was quantified
using the Kodak image station 4000R (Arbitrary unit; ,: below detection level).
doi:10.1371/journal.pone.0115944.g007
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H1-HFBI immunogenicity was evaluated by subcutaneous vaccination of 10
female CD1 mice with 50 mg of purified H1-HFBI formulated with Freund’s
adjuvant. Pre-immune sera were collected before the first injection, and blood
samples were collected after the 4th and the 6th boost. The three samples were
analyzed for their ability to recognize a recombinant Influenza A/Texas/05/2009
(H1N1) ectodomain produced in mammalian cells by endpoint titer ELISA
(Fig. 9a). Sera of mice immunized with H1-HFBI displayed significantly higher
anti-HA titer than the pre-immune sera (p53.8.1024). An average HA-specific
antibody titer of 25,600 was obtained for the samples collected after the 4th boost,
and no statistical difference was observed between the samples collected after the
4th or the 6th boost (p50.18) (Fig. 9b).
The immune response to H1-HFBI results in neutralizing activity
The last step consisted of demonstrating the neutralizing properties of sera from
H1-HFBI-vaccinated mice. A reliable test is the hemagglutination inhibition test.
Serum samples were incubated with inactivated A/Texas/05/2009 (H1N1) virus,
and potential neutralizing antibodies were expected to bind viral receptor binding
domains and prevent attachment of the virus to chicken RBCs (Fig. 10).
Therefore hemagglutination is prevented when antibodies are present. The highest
serum dilution that prevents hemagglutination is designated as the hemaggluti-
nation inhibition titer of the serum. None of the pre-immune sera inhibited
hemagglutination. Sera collected after the 4th and 6th boost presented a
hemagglutination inhibition mean of 83 and 70, respectively. This difference was
Fig. 8. Selective ammonium sulfate precipitation of ATPS-purified H1-HFBI. Solid ammonium sulfate
corresponding to 5% or 10% saturation was added to ATPS-purified H1-HFBI samples (4 mg/ml), left for 1 h
at 4˚C, and centrifuged. The pellet (P) was dissolved in the same volume of PBS as the supernatant volume
(SN).
doi:10.1371/journal.pone.0115944.g008
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not statistically significant. We can therefore conclude that H1-HFBI expressed in
N. benthamiana is able to induce an immune response with neutralizing activity.
Discussion
Plants have been reported to be an alternative and reliable expression system for
seasonal and pandemic influenza vaccines [27]. Transient expression is the most
suitable production method regarding influenza pandemics or zoonotic out-
Fig. 9. ELISA-based assessment of the immune response of H1-HFBI-immunized mice. (a) Ten mice
were immunized with H1-HFBI as indicated in the Experimental procedures. Anti-HA antibodies were assayed
by ELISA in the pre-immune sera (open circle) and the sera collected after the 4th (blue triangle) and 6th (red
square) boost. Plates were coated with 5 mg/ml of recombinant Influenza A/Texas/05/2009(H1N1) ectodomain
expressed in mammalian cells (Sino Biologicals, 11085-V08H). HRP-conjugated anti-mouse secondary
antibody was used for detection. HA titer was calculated as the highest dilution giving a signal higher than
three times the signal coming from the negative control. (b) Box and whisker analysis of antibody titers
obtained after endpoint ELISA titer analysis of the test groups. Each dot represents the antibody titer from an
individual mouse. (p-values 50.18 (boost 4/boost 6), 1.8.1024 (boost 4/pre-immune), 3.8.1024 (boost 6/pre-
immune))
doi:10.1371/journal.pone.0115944.g009
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breaks. It has been demonstrated that a time period of 3–4 weeks is sufficient to
produce a large dose of vaccines [10, 28].
We successfully transiently expressed the hemagglutinin ectodomain of
Influenza A/Texas/05/2009 (H1N1) in N. benthamiana leaves and obtained a high
accumulation level of 8.6% TSP. This was obtained by combining transient
transformation, which allows yields well over those obtained in stable transgenic
plants, and the pEAQ-HT binary vector, which contains the CPMV UTR’s (acting
as translation enhancers) as well as the P19 gene, which prevents silencing [21].
However, three further improvements were made in this work which resulted in
enhanced H1 expression. First, the utilization of an A. tumefaciens strain which
constitutively expressed virG made phenolics unnecessary to activate transfor-
mation ([24]. As a consequence, the accumulation of H1-HFBI was enhanced by
30% when acetosyringone was omitted from the inoculation medium (S3 Fig.).
Second, using the En2PMA4 promoter instead of the CaMV 35S promoter was
probably an additional asset, since this exchange allowed a 50% increase of GFP
expression in transient expression (S2 Fig.). Third, fusion of H1 to HFBI increased
expression by ,2.5 fold (S4 Fig.). The effect of HFBI fusion on HA accumulation
is consistent with the 2 fold and 2–3 fold increase of GFP-HFBI reported by
Joensuu and co-workers [17] and Gutierrez and co-workers [29], respectively.
However, our results contrast with those of Phan and co-workers [19], who
showed no yield improvement by fusing HFBI to an H5 ectodomain [19]. This
discrepancy might be explained by the weak sequence identity between the H1 and
H5 HAs (63%), and the possibility that the effect of HFBI on the accumulation
level is protein dependent, as this was observed for ELP fusions [30]. Taken
together, the removal of AS, the use of the En2PMA4 promoter and the HFBI
fusion led to a 330% increase of H1 expression.
Direct comparisons between our data and those previously obtained for the
expression of HA in plants is not straightforward for several reasons: the HA
Fig. 10. Neutralizing properties of antibodies induced by H1-HFBI. Sera from the ten vaccinated mice
were serially 2-fold diluted and incubated with inactivated virus for 30 min, and then RBCs were added. Pre-
immune sera were used as a negative control. Hemagglutination inhibition titers were determined. The mean
for each test group was calculated, and bars represent SD.
doi:10.1371/journal.pone.0115944.g010
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origin (virus strain), the portion of HA that is expressed, and the yield calculation
(% of TSP or % leaf fresh weight) differ. However, in our hands, since TSP
represents ,6 mg protein/g leaf fresh weight, a H1-HFBI yield of 9.7% TSP is
equivalent to ,600 mg H1-HFBI/kg leaf fresh weight or ,510 mg H1/kg leaf
fresh weight after subtracting the HFBI counterpart. This value exceeds those
reported for the transient expression of the complete HA (50 mg/kg; [7]) and is
within the same range of HA soluble portions expressed with a launch vector
system which involves components of a plant RNA virus (400–1300 mg/kg; [9]).
It is also much higher than the 0.05% TSP observed for an H5-HFBI fusion or the
0.5% TSP seen for H5 fused to an elastin-like protein [19]. However, these results
were obtained with stable transformation which is known to exhibit reduced
performance when compared with transient expression.
Unlike H1, H1-HFBI was located in protein bodies (Fig. 3). This might explain
why the HFBI fusion resulted in increased accumulation, as it has been suggested
that protein bodies prevent proteolytic degradation [31]. Untagged H5 was partly
found in protein bodies, but to a lesser extent than H5-HFBI [19]. HA-HFBI
deglycosylation by EndoH strongly supports the ER localization of protein bodies,
as EndoH specifically cleaves high-mannose N-glycans added in the ER, but not
complex N-glycans typically found in glycoproteins that reach the Golgi. As a
decrease of about 10 kDa of H1-HFBI was observed upon EndoH treatment
(Fig. 4), and since N-glycosylation increases by ,2.5 kDa the size of a protein
[32], we can guess that four out of the six predicted glycosylation sites [33] are
glycosylated.
ATPS purification was shown to be effective for H1-HFBI recovery from plant
leaf extracts (Fig. 5). However, a few proteins contaminated the purified fraction.
They correspond to abundant TSP proteins and were identified by mass
spectrometry (S1 Table). Three out of five identified contaminants are
chloroplastic proteins which belong to the oxygen-evolving complex [34]. This
complex is one of the three sub-complexes that compose the plant photosystem II,
the function of which is to harvest light energy. H1-HFBI without visible
contaminants was obtained by combining ATPS purification with differential
ammonium sulfate precipitation (Fig. 8). Combining these two approaches also
allowed for an increase in the amount of surfactant used during ATPS. As the
recovery efficiency is proportional to the concentration of surfactant used [17],
using 8 to 10% instead of 4% of Triton X-114 might improve H1-HFBI recovery
that was about 70% in this study. The higher surfactant concentration implies a
larger volume of the lower phase, but this is unimportant as the following step
(ammonium sulfate precipitation) concentrates the purified proteins. This
combined purification has the advantage to be scalable, as ATPS has been shown
to be efficient up to 20 L [18].
Recombinant hemagglutinin monomers can aggregate in HMWO but this
varies according to the viral strain, the expression system, the genetic
modifications, and the purification method [26]. Protein aggregates are of interest
in vaccination because they are more immunogenic than monomers, although
recent concerns about safety were raised [35]. Purified plant-produced H1, H5,
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and H5-ELP ectodomains have been expressed as monomers [20, 36], but another
example from the literature showed plant-produced HMWO [26]. Also, HA from
the same influenza strain used in the present study was expressed in Escherichia
coli as a HMWO [37]. In this study, we observed that the H1 ectodomain alone
was probably expressed as monomers, as no hemagglutination was observed while
the H1 ectodomain fused to HFBI was expressed as both monomers and
oligomers, with a preponderance of the latter. This suggests that the formation of
those oligomeric structures is due to HFBI interactions, which is another
advantage of this carrier. Yet, this effect may be protein and expression dependent,
as it has been shown that HFBI self-interacts at a given concentration [38].
Additionally, in order to increase the oligomeric form and enhance the
immunogenicity of H1-HFBI, a trimerization motif such as GCN4-PII could be
inserted between HA and HFBI. A fraction of H1-HFBI had a size close to that of
H1 (Fig. 2), suggesting that cleavage occurred in the linker region. Changing the
latter could further improve the yield of H1-HFBI.
The hemagglutination assay was chosen to assess the biological activity and
consequently the proper folding of H1-HFBI. This test was made possible because
of the presence of oligomeric structures, whereas monomers are not able to
agglutinate RBCs. A positive response using a dose as low as 0.3 mg/ml was
obtained. This demonstrates that hydrophobin fusion and the purification
method used did not impact the biological activity.
H1-HFBI was shown to induce a significant serum antibody titer in vaccinated
mice (Fig. 10). This was demonstrated by ELISA with an HA ectodomain
produced in mammalian cells in order to eliminate a potential response coming
from anti-hydrophobin antibodies and to confirm the specificity of the induced
anti-HA antibodies. H1-HFBI is also expected to be protective in mice, as the
calculated hemagglutination inhibition titer was 83, while the minimal titer
required for a vaccine to be protective in humans is 40 [39]. Blood samples were
collected after the 4th and the 6th booster immunization but no significant
differences were observed between the two samples. Regarding pandemics, when
part of the population is immunologically nai¨ve to the emerging viral strain, two
vaccine doses may be required, while one dose should be enough for people with
preexisting immunity against the virus lineage. Therefore, four booster
immunizations is too high and a dose-ranging study has to be performed to
investigate the potential of this vaccine candidate. This study should also include
different adjuvants such as Qiul A or AbISCO. One might wonder whether
injection of the fungal hydrophobin to animals and humans could trigger
deleterious effects. Hydrophobins have a nontoxical nature [40] and prevent
immune recognition of fungal spores, suggesting that they are not immunogenic
[41]. This suggests that hydrophobin fusion is safe for antigen design even though
further investigation must be performed. As an exploratory experiment, the
presence of anti-HFBI antibodies in a vaccinated mouse serum was assessed by
Western blotting of HFBI fused to another protein, the Green Fluorescent Protein
(GFP) as well as of unfused GFP as a control, both expressed in N. benthamiana
(S6 Fig.). The serum did not show HFBI recognition. However, Nakari-Seta¨la¨ and
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colleagues were able to produced anti-HFBI antibodies by immunization of
rabbits [42], indicating that the protein might be immunogenic. Therefore,
further investigations are required to determine the HFBI immunogenicity and its
impact on the immunogenicity of the fused protein. In case of a negative impact
or the formation of anti-HFBI antibodies that might be deleterious for the patient,
the addition of a proteolytic cleavage site between H1 and HFBI could be
considered. This cleavage could also be useful to remove a potential trimerization
motif added to stabilize the oligomeric form into a more homogenous product.
Many efforts have been carried out to find an alternative to the current egg-
based vaccine technology. In this study, we investigated a hydrophobin fusion to a
recombinant hemagglutinin ectodomain. This fusion was shown to enhance the
accumulation level and to allow rapid, easy, and scalable purification while the
fused protein remained biologically active, was immunogenic, and induced
neutralizing antibodies in mice. Transient expression of H1-HFBI is therefore a
promising approach to produce seasonal and/or pandemic influenza vaccines.
Experimental Procedures
Ethics statement
The experiments, maintenance and care of mice complied with the guidelines of
the European Convention for the Protection of Vertebrate Animals used for
Experimental and other Scientific Purposes (CETS n˚ 123). The protocol was
approved by the Committee on the Ethics of Animal Experiments of the
University of Lie`ge, Belgium (Permit Number: 06-594). All efforts were made to
minimize suffering.
Materials
Escherichia coli Top 10 or Agrobacterium tumefaciens LBA4404virG (van der Fits
et al., 2000) were used for cloning experiments and plant transformation,
respectively. Nicotiana benthamiana plants were grown in compost in a growth
chamber with 16 h of light (200 mmol.s21.m22) at 25 C˚ and 8 h of darkness at
19 C˚.
Nicotiana tabacum cv. Bright yellow-2 (BY-2) [43] suspension cells were grown
in MS medium (30 g/l sucrose, 4.4 g/l Murashige and Skoog medium, 0.2 g/l
KH2PO4, 50 mg/l myo-inositol, 2.5 mg/l thiamine, 0.2 mg/l 2-4D, pH 5.8
(KOH)) at 25 C˚ under dark light conditions with agitation at 90 rpm. The
cultures were diluted 1:20 in fresh medium every week. Transformed cells were
grown in medium supplemented with 100 mg/ml of kanamycin.
Construction of the H1 and H1-HFBI expression vectors
The pEAQspecialK-HT plasmid [21] was used as an expression vector. The initial
p35S promoter was replaced by the Nicotiana plumbaginifolia H+-ATPase PMA4
promoter reinforced with two copies of the 35S enhancer [23]. The DNA sequence
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corresponding to codons 1 to 566 of the influenza A/Texas/05/2009(H1N1) HA
gene was optimized for plant expression and synthesized by GenScript
(Piscataway, USA). The sequence encoding the HA ectodomain (codons 18–529)
was amplified from this sequence using the primers HA-Chit (59
TATCCTCGGCCGAAGATACCCTCTGCATTGG 39) and HA-HFBIR (59
CGAGTGAACCACCACCCTGATAGATCCTGGTACTC 39). This was fused by
overlap extension PCR to the signal peptide sequence (codons 1 to 21) of the
Arabidopsis thaliana basic endochitinase (Accession number: P19171) amplified
from pSK-chit-OspA [44] using the primers chitAgeI
(59AACACCGGTATGAAGACTAATCTTTTTCTC 39, AgeI site underlined) and
Chit-HA (59 CCAATGCAGAGGGTATCTTCGGCCGAGGATAATGAT 39). The
resulting chit-HA fragment was cloned into the pGEM-T Easy vector and
sequenced. A DNA sequence corresponding to a GGGSGGGS linker, codons 23 to
97 of the HFBI gene from Trichoderma reseei (P52754), a GGGG linker, and the
KDEL ER-retrieval motif was optimized for plant expression and synthesized by
GenScript (Piscataway, USA). The sequence was amplified by PCR with the
primers HA-HFBIF (59 GAGTACCAGGATCTATCAGGGTGGTGGTTCACTCG
39) and HFBIXhoI (59 TTGCTCGAGTCATAACTCATC39, XhoI underlined). The
HFBI-KDEL amplicon was fused by overlap extension PCR to the chit-HA
fragment. The resulting PCR product was introduced into pEAQ-HT using AgeI/
XhoI to generate the pEAQ-H1-HFBI binary plasmid.
The untagged H1 gene construct was obtained by PCR from the H1-HFBI
construct using the primers chitAgeI and KDELXhoI (59
TTGCTCGAGCTGATAGATCCTGGTACTCTC 39, XhoI underlined) and cloned
into pEAQ-HT to give pEAQ-H1-HT. The nucleotide and amino acid sequences
of H1-HFBI and H1 are displayed in S1 Fig.
Plant transient transformation
The pEAQ-H1-HT and pEAQ-H1-HFBI-HT binary plasmids were introduced
into A. tumefaciens LBA4404 virG by electroporation. The A. tumefaciens strains
were grown overnight at 28 C˚ in 2YT medium (1.6% bacto-tryptone, 1% bacto-
yeast-extract, 0.1% glucose, 0.02% MgSO4) supplemented with 20 mg/ml
rifampicin, 40 mg/ml gentamycin, and 50 mg/ml kanamycin. The cells were
harvested by centrifugation (5,000 g, 5 min, 15 C˚), washed three times in
infiltration medium (10 mM MES monohydrate, 10 mM MgCl2, pH 5.3 (KOH)),
and resuspended in infiltration medium at a final OD600 of 0.6. N. benthamiana
leaves were then infiltrated on the abaxial side through the stomata using a
syringe. The plants were incubated for 6 days under routine culture conditions.
N. tabacum BY-2 cell stable transformation
N. tabacum BY-2 suspension cells were transformed by co-cultivation with A.
tumefaciens as described previously [44]. Transgenic calli were selected on MS
medium supplemented with 100 mg/ml kanamycin.
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Protein electrophoresis and Western blotting
The protein content of the different samples was determined using the Bradford
method [45].
Proteins were solubilized in SDS loading buffer (80 mM Tris-HCl, pH 6.8, 2%
SDS, 10% glycerol, 0.005% bromophenol blue, 60 mM DTT, 1 mM PMSF, and
1 mg/ml each of leupeptin, aprotinin, antipain, chymostatin, pepstatin), boiled for
5 min, and separated by SDS-PAGE (10% polyacrylamide gel).
For colloidal Coomassie blue staining, gels were incubated at room temperature
for 2 h in fixation solution (50% ethanol, 2% phosphoric acid), washed three
times with water, stained overnight in staining solution (34% methanol, 17%
ammonium sulfate, 3% phosphoric acid, 700 mg/l of Coomassie Brilliant Blue G-
250 (Serva, Heidelberg, Germany), and destained in water.
For Western blotting, proteins were electrotransferred onto a polyvinylidene
fluoride membrane, then the membrane was saturated, incubated first with goat
anti-influenza A (1:1,000, OBT1551, Abdserotec, UK) for 1 h at room
temperature, and incubated a second time with anti-goat HRP-conjugated
(1:10,000, A5420, Sigma, St-Louis, MO) for 1 h at room temperature. The
membrane was incubated for 2 min with Lumi-light (Roche, Switzerland) and the
signals were quantified using the Kodak Image Station 4000R (Eastman Kodak
company, Rochester, NY).
To obtain a rough estimation of the expression level of recombinant H1 and
H1-HFBI proteins, an immunoblotting technique was applied using the
extracellular domain of a recombinant Influenza A/Texas/05/2009(H1N1)
hemagglutinin produced in human cells (11085-V08H, Sino Biologicals, China) as
a standard. The soluble fraction obtained after homogenization of agro-infiltrated
leaves was serially diluted to obtain band intensities that were similar to the band
intensity of the standard protein used at varied amounts (50, 100, 200, 500 ng).
Band intensities were quantified using Kodak Image Station 4000R software. For
H1-HFBI quantification, 16 independent samples were analyzed.
Endoglycosidase H treatment
Leaf protein (5 mg) samples containing H1-HFBI were diluted in 50 mM sodium
citrate pH 5.5 (HCl), 0.5 mM PMSF. Then, 0.2 U/ml Endoglycosidase H (Roche)
was added. After incubation at 37 C˚ for 0, 15, or 60 min, the reaction was stopped
by the addition of SDS loading buffer.
In situ immunolocalization
Three-day-old transgenic N. tabacum BY-2 cell cultures (1.6 ml) were harvested
by centrifugation at 900 g for 10 min (Mikro 20, Hettich Zentrifugen), and the
location of H1-HFBI and untagged H1 were identified by in situ immunoloca-
lization as described in [46] using FITC-conjugated anti-influenza (1:20 dilution;
Ab20388, Abcam, UK).
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H1-HFBI extraction and purification
Agro-infiltrated leaves were frozen in liquid nitrogen and homogenized using a
mortar and a pestle. The resulting powder was then resuspended in 10 volumes of
ice-cold PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4)
supplemented with 1 mM PMSF, and homogenized in a potter or a shaker for
small or large volumes, respectively. The homogenate was clarified by
centrifugation at 15,000 g for 20 min at 4 C˚. Membrane proteins were discarded
by ultracentrifugation at 125,000 g for 30 min at 4 C˚.
For ATPS, TSP were pre-warmed in a water bath until the temperature reached
28 C˚. TSP were then mixed vigorously with 4% (w/v) of Triton X-114 and
introduced into a separation funnel. The two phases were allowed to separate for
15 min at 28 C˚. The bottom phase was recovered and detergent was removed by
the addition of isobutanol (10 times the Triton X-114 volume). After
centrifugation at 5,000 g for 5 min at room temperature, the new bottom phase
containing H1-HFBI was recovered.
ATPS-purified H1-HFBI was further purified by adding solid ammonium
sulfate up to 5% or 10% of the final concentration. The solution was then stirred
for 1 h at 4 C˚ and centrifuged at 20,000 g for 15 min at 4 C˚. The supernatant was
discarded and the remaining pellet was dissolved in PBS.
Protein analysis by mass spectrometry
The bands corresponding to proteins were excised from the gel, treated with
trypsin, and analyzed by MS/MS, as described in [47] and as detailed in S1 Table.
Gel filtration chromatography
For size exclusion chromatography, a Superdex G200 column (GE Healthcare,
UK) (106300 mm) was used coupled to an A¨kta Explorer (GE Healthcare)
purification system. After column equilibration with PBS, 100 ml of gel filtration
standards (Bio-Rad, #151-1901) were injected and a flow rate of 1 ml/min was
applied until the last standard was eluted. Then, a 500 ml ATPS-purified sample
was applied to the column under the same conditions. Effluents were collected in
1 ml fractions.
Hemagglutination assay and hemagglutination inhibition assay
Functional activity of H1-HFBI was evaluated using a hemagglutination assay
according to standard procedures [48]. Recombinant H1-HFBI was diluted to a
final concentration of 4 mg/ml in PBS, and 50 ml aliquots were serially two-fold
diluted in U-bottom 96-well plates. After the addition of 50 ml of 1% (w/v) RBCs,
the plates were incubated for 30 min at 20 C˚. Bovine serum albumin was used as a
negative control.
The hemagglutination inhibition assay was based on standard procedures as
well [46]. Influenza A/Texas/05/2009 virus purified from allantoi¨c fluid and
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formol-inactivated was diluted to a final concentration of 8 HAU/50 ml after
quantification by a hemagglutination assay. Sera from immunized mice were
diluted with three volumes of Cholera filtrate containing Receptor Destroying
Enzyme (Sigma, C8772-1VL) and incubated for 16 h at 37 C˚, then heat
inactivated for 30 min at 56 C˚. Two-fold dilution of inactivated sera was followed
by incubation with 4 HAU of A/Texas/05/2009 virus for 30 min at 20 C˚. Chicken
erythrocytes (1%) were added and incubated for an additional 40 min at 20 C˚.
The HAI titer was calculated as the reciprocal of the highest dilution that
produced complete hemagglutination inhibition.
Mice immunization
A group of 10 8 week-old female CD1 mice were blood sampled before
vaccination. The mice were then vaccinated intraperitoneally with 50 mg of
purified H1-HFBI every two weeks for a total of 6 hyperimmunizations. The
vaccine was formulated with Complete Freund’s adjuvant for the first two
immunizations, and with Incomplete Freund’s adjuvant for the booster
immunizations. Blood samples were collected after 4 boosts using a slight incision
in the mice tails. Two weeks after the 6th boost, the mice were killed humanly by
an overdose of pentobarbital and an exsanguination. The sera collected were used
for indirect ELISA and hemagglutination inhibition assay.
Indirect ELISA
Microtiter plates were coated with 100 ml/well of 5 mg/ml (in PBS) of extracellular
domain of recombinant Influenza A/Texas/05/2009 (H1N1) hemagglutinin
produced in human cells (Sino Biologicals, 11085-V08H) and incubated for 16 h
at 4 C˚. The plates were then washed three times in PBST (0.1% Tween 20 in PBS)
and saturated for 1 h at room temperature with 200 ml/well of PBS supplemented
with 5% dried non-fat milk. After three additional washing steps, 100 ml of a 1:100
dilution of sera from the immunized mice were serially two-fold diluted and
incubated for 90 min at 37 C˚. The plates were then washed three times with PBST
and incubated for 1 h at room temperature with 100 ml/well of a 1:10,000 dilution
of anti-mouse HRP-conjugated IgG (Biognost Millipore, AP308P). After four
washes, 100 ml/well of o-phenylenediamine peroxidase substrate (Sigma) in citrate
buffer (0.05 M Na2HPO4, 0.025 M citric acid) was added. The reaction was
stopped after 15 min with 50 ml of 1 M H2SO4 and the absorbance measured at
490 nm (Model 550, Microplate Reader; Bio-Rad, Hercules, CA).
Supporting Information
S1 Fig. Nucleotide and amino acid sequence of H1-HFBI. Purple: A. thaliana
endochitinase signal peptide, White: Influenza A/Texas/05/2009 (H1N1) ectodo-
main, Red: linker, Yellow: HFB I, Green: KDEL retention signal.
doi:10.1371/journal.pone.0115944.s001 (DOCX)
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S2 Fig. Transient GFP expression comparison in N. benthamiana leaves
between two strong transcriptional promoters. Leaves were infiltrated with an A.
tumefaciens strain containing the pEAQ-HT vector with the GFP gene driven by
the p35S or En2PMA4 promoter. A leaf transformed with an empty pEAQ-HT
vector was used as a negative control. A TSP fraction was prepared at 6 dpi. (a)
Twenty mg of TSP were analyzed by SDS-PAGE and the gel was stained with
colloidal blue. The large Rubisco subunit is indicated (*), and the GFP is indicated
by an arrow. (b) The GFP content of six independent samples (50 mg TSP) for
each promoter was quantified by fluorimetry (excitation at 395 nm and emission
at 508 nm).
doi:10.1371/journal.pone.0115944.s002 (PDF)
S3 Fig. Impact of acetosyringone in the infiltration medium on HA-HFBI
accumulation. Following agroinfiltration with the H1-HFBI construct in the
presence (+) or absence (2) of acetosyringone in the infiltration medium, total
soluble proteins (TSP) were extracted at 6 dpi and the band corresponding to H1-
HFBI was quantified by Western blotting. (n516, bars 5 SD, p-value 50.0011).
doi:10.1371/journal.pone.0115944.s003 (PDF)
S4 Fig. Relative quantification of H1-HFBI and H1 accumulation. The H1 and
H1-HFBI constructs were transiently expressed in N. benthamiana leaves. One
construct was infiltrated on one half of the leaf and the other one on the other
half. The H1-HFBI TSP fractions (1 mg) were diluted two, three, or four times and
compared to undiluted H1 TSP fractions (1 mg) by Western blot analysis. Values
obtained after quantification with the Kodak Image Station 4000R are displayed
below each sample in arbitrary units.
doi:10.1371/journal.pone.0115944.s004 (DOCX)
S5 Fig. Hemagglutination assay of purified HA-HFBI. Hemagglutination assay
was performed as indicated in the Experimental procedures using serial two-fold
diluted samples of dissolved ammonium sulfate precipitate of H1-HFBI (duplicate
R1, R2). The upper row contains BSA as a negative control.
doi:10.1371/journal.pone.0115944.s005 (PDF)
S6 Fig. Evaluation of anti-HFBI antibodies in immunized mouse serum.
Samples containing H1-HFBI, GFP-HFBI or GFP (15 mg TSP) transiently
expressed in N. benthamiana were analyzed by Western blotting using a 1:200
diluted serum from mouse 6 immunized with H1-HFBI and a 1:5000 dilution of a
HRP-conjugated anti-mouse secondary antibody. The membrane was then
stripped in 0.4N NaOH for 3 min and then incubated with a polyclonal anti-GFP
antibody and a polyclonal anti-rabbit secondary antibody. Samples coming from a
leaf infiltrated with an empty vector and a commercial recombinant H1 expressed
in mammalian cells (rHA(+)) were used as negative and positive controls,
respectively. Note thatadditional bands were detected with the mouse serum at a
size similar to unfused GFP. They probably do not correspond to GFP as the fused
GFP-HFBI is not recognized.
doi:10.1371/journal.pone.0115944.s006 (DOCX)
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S1 Table. Identification of the proteins contaminating the ATPS-purified
sample1. 1Method: The acquired spectra were analyzed using the Applied
Biosystems GPS Explorer (version 3.6) and the Matrix Science MASCOT
algorithm in the NCBI N. benthamiana database and the NCBI N. benthamiana
EST database, as described in Duby et al. (2010). Reverse phase separation of
peptides was completed on an Ultimate 3000 chromatography chain
(ThermoFisher Scientific) using a C18 PepMap 100 analytical column (150 mm,
3 mm i.d., 100 A˚), (ThermoFisher Scientific). Previously the sample was dissolved
in 0.025% (v/v) TFA and 5% (v/v) ACN and desalted using a C18 Pep Map 100
pre-column (10 mm, 5 mm i.d., 100 A˚). Peptides were backflushed onto the
analytical column with a flow rate of 300 nL/min by a 180 min linear gradient
from 8 to 76% (v/v) ACN in water containing 0.1% (v/v) TFA in buffer A and
0.085% (v/v) TFA in buffer B. The eluted peptides were mixed with a-cyano-4-
hydrocinnamic acid (4 mg/mL in 70% ACN/0.1% TFA) and spotted directly onto
a MALDI target using a Probot system (ThermoFisher Scientific). 2The band
numbers correspond to those annotated in Fig. 5.
doi:10.1371/journal.pone.0115944.s007 (PDF)
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